Business Wire

IDEMIA

27.4.2020 03:02:08 CEST | Business Wire | Press release

Share
IDEMIA Provides Seamless Biometric Access Control to Digital Garage’s New Headquarters in Japan

IDEMIA, the global leader in Augmented Identity, today announced the first deployment of MorphoWave ™ Compact in Japan to provide high security and convenience for businesses and the public.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200426005034/en/

The contactless fingerprint technology was installed in the new headquarters of Digital Garage, located in the famous Shibuya district in Tokyo. They are the first to experience such a fast, frictionless and seamless biometric access control in Japan, through this deployment conducted in collaboration with IDEMIA’s official value added partner JAPAN AEROSPACE CORPORATION (JAC). JAC also conducted the network configuration using MorphoWave ™ Compact to integrate with Digital Garage’s system.

The Shibuya headquarters’ 450 employees enjoy all the benefits of MorphoWave ™ Compact for office and floor access control. They can authenticate their biometrics by a touchless “wave” gesture of the hand within the MorphoWave ™ Compact reader, which ensures efficiency, convenience, speed and security. This is also a more hygienic verification method since the users’ fingers are not in contact with the biometric sensor, whether accessing the building and floor or being enrolled.

MorphoWave ™ Compact is a biometric reader equipped with 3D fingerprint technology powered by Artificial Intelligence (AI) that can scan four fingers in less than one second. The algorithms in the biometric system ensure high matching accuracy and it enables up to 100,000 users being identified by one device. In a broader view, MorphoWave ™ Compact eliminates the need for cards, remembering PINs, tailgating and importantly, the concern of multiple people touching a surface.

Nezu Nobuyoshi, Managing Director and Vice President of Sales in IDEMIA Japan said: “With the increasing number of access points in buildings and offices, having touchless 3D fingerprint authentication technology is increasingly important to achieve convenience and maximum security. As a leader in biometrics, we want to provide entities with an advanced biometric technology that is convenient to use and allows users to identify themselves without complications.”

A spokesperson from Digital Garage said: “We are proud to be the first in Japan to implement this touchless 3D fingerprint technology for biometric access control, which ensures accurate identification of our employees and visitors. IDEMIA’s technology is the ideal fit for us, thanks to its versatile and easy deployment, accuracy and reliability in fingerprint matching.”

-END-

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With 13,000 employees around the world, IDEMIA serves clients in 180 countries.

For further information, go to www.idemia.com / And follow @IdemiaGroup on Twitter

About Digital Garage

Digital Garage is engaged in two recurring businesses: the fintech business, which provides a package of various payment methods to e-commerce operators and face-to-face retailers, and the marketing business, which provides integrated solutions in the digital and real fields. In addition, it is developing investment and development businesses for promising companies around the world. In addition, in collaboration with our core partners, they operate DG Lab, an open innovation R&D organization. As a company that creates new "contexts" in the Internet age, they will connect various businesses and create innovative services.

About JAC

JAPAN AEROSPACE CORPORATION (JAC) has a history of more than 60 years and a core aerospace company of ITOCHU Group, providing unique and specialized services based on the concept of "only one" and "niche top". JAC offers value added "engineering and technical” services and propose business solutions, mainly relating to national security and social infrastructure along with improvement of safety, comfortability and affordability to the Japanese market.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye